FDA Rejects Moderna mRNA Flu Vaccine
Analysis based on 8 articles · First reported Feb 10, 2026 · Last updated Feb 11, 2026
The United States — Food and Drug Administration's refusal to consider Moderna's flu vaccine application signals increased regulatory hurdles for mRNA technology in the US, potentially impacting Moderna's stock price and future revenue streams. This decision also reflects a broader shift in vaccine scrutiny under Robert F. Kennedy Jr., which could affect other pharmaceutical companies developing similar technologies.
The United States — Food and Drug Administration has refused to consider Moderna's application for a new mRNA flu vaccine, issuing a 'refusal-to-file' letter. The agency, under Health Secretary Robert F. Kennedy Jr., cited concerns with Moderna's 40,000-person clinical trial, stating it did not compare the vaccine to the 'best-available standard of care' in the United States. This decision comes amidst heightened scrutiny of mRNA technology by Robert F. Kennedy Jr., who has previously criticized such vaccines and canceled over $500 million in related contracts. Moderna CEO Stéphane Bancel expressed disappointment, noting the United States — Food and Drug Administration found no safety or efficacy concerns with their product. Moderna has requested an urgent meeting with the United States — Food and Drug Administration and is pursuing approval in Europe, Canada, and Australia.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard